Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.

Abstract excerpt

Introduction: While there has been an improvement in the treatment of mantle cell lymphoma (MCL) in both median progression-free survival (PFS; >7-8 years) and overall survival (OS; >10-12 years), patients with high-risk features such as high risk MIPI (mantle cell international prognostic index), high Ki-67 (≥30%), or blastoid variants still carry poor outcome with a median OS of 3 years. Furthermore, patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers
• Share to Lymphoma, Mantle-Cell
• Share to Mutation